Literature DB >> 9182534

Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6.

K K Kuropatwinski1, C De Imus, D Gearing, H Baumann, B Mosley.   

Abstract

Oncostatin M (OSM), leukemia inhibitory factor (LIF), and interleukin-6 (IL-6) induce expression of a similar set of acute phase plasma protein genes in hepatic cells. The redundant action of these cytokines has been ascribed to the involvement of the common signal-transducing receptor subunit, gp130, in combination with cytokine-specific, ligand-binding subunits. To define the specificity of the signal transduction by the LIF/OSM receptor (a heterodimer of gp130 and LIF receptor (LIFR)) and the OSM-specific receptor (a heterodimer of gp130 and OSM receptor (OSMR)), we reconstituted the receptor function by transfection into receptor-negative Hep3B hepatoma cells. Both receptors activate DNA binding activity of STAT1, -3, and -5B and induce gene transcription through IL-6-responsive elements. The signaling-competent cytoplasmic domain regions of OSMR and LIFR were defined by the analysis of progressive carboxyl-terminal deletion constructs. The 36 residue carboxyl-terminal region containing the distal box 3 sequence motif of OSMR is required for signal transduction by the OSM-specific receptor. In contrast, signaling by LIFR did not display the same requirement for receptor domains and was not strictly dependent on the box 3 elements. The signaling by endogenous LIF and OSM receptors differed from that by IL-6R by the prominent activation of STAT5 as shown in the mouse hepatoma cell line, Hepa-1. The data suggest that the signaling specificity of the receptors for the three cytokines is determined by the composition of the cytoplasmic domains associated in the signal-competent receptor complex and that the signaling is not identical among these cytokine receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9182534     DOI: 10.1074/jbc.272.24.15135

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Gene expression profiling of long-term changes in rat liver following burn injury.

Authors:  Arul Jayaraman; Tim Maguire; Murali Vemula; Deukwoo W Kwon; Marina Vannucci; Francois Berthiaume; Martin L Yarmush
Journal:  J Surg Res       Date:  2007-08-28       Impact factor: 2.192

2.  Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.

Authors:  Kathryn L Pothoven; James E Norton; Kathryn E Hulse; Lydia A Suh; Roderick G Carter; Erin Rocci; Kathleen E Harris; Stephanie Shintani-Smith; David B Conley; Rakesh K Chandra; Mark C Liu; Atsushi Kato; Nirmala Gonsalves; Leslie C Grammer; Anju T Peters; Robert C Kern; Paul J Bryce; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-04-01       Impact factor: 10.793

Review 3.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

4.  A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.

Authors:  Hui Xiao; Hemant Kumar Bid; David Jou; Xiaojuan Wu; Wenying Yu; Chenglong Li; Peter J Houghton; Jiayuh Lin
Journal:  J Biol Chem       Date:  2014-10-13       Impact factor: 5.157

5.  Differential effects of oncostatin M and leukaemia inhibitory factor expression in astrocytoma cells.

Authors:  A Kasza; K Rogowski; W Kilarski; R Sobota; T Bernas; J Dobrucki; J Travis; A Koj; M Bugno; T Kordula
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

Review 6.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  Crif1 is a novel transcriptional coactivator of STAT3.

Authors:  Min-chul Kwon; Bon-Kyoung Koo; Jin-Sook Moon; Yoon-Young Kim; Ki Cheol Park; Nam-Shik Kim; Mi Yi Kwon; Myung-Phil Kong; Ki-Jun Yoon; Sun-Kyoung Im; Jaewang Ghim; Yong-Mahn Han; Sung Key Jang; Minho Shong; Young-Yun Kong
Journal:  EMBO J       Date:  2008-01-17       Impact factor: 11.598

Review 8.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

9.  A dual role for oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo.

Authors:  Paul G Tiffen; Nader Omidvar; Nuria Marquez-Almuina; Dawn Croston; Christine J Watson; Richard W E Clarkson
Journal:  Mol Endocrinol       Date:  2008-10-16

10.  Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease.

Authors:  Julia Dambacher; Florian Beigel; Julia Seiderer; Dirk Haller; Burkhard Göke; Christoph J Auernhammer; Stephan Brand
Journal:  Gut       Date:  2007-04-20       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.